Disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The promoter and promoter group of Ind-Swift Laboratories Limited acquired 45,15,495 equity shares (5.53% of the company's share capital) pursuant to a scheme of amalgamation of Ind-Swift Limited (Transferor Company) with Ind-Swift Laboratories Limited (Transferee Company). The shares were allotted on August 25, 2025, increasing the company's equity share capital from INR 73.49 crores to INR 81.61 crores. As a result, the promoter group's aggregate holding rose from 37.72% (2,77,18,783 shares) to 39.50% (3,22,34,278 shares) of the total share capital. Essix Biosciences Limited, the flagship promoter entity, individually increased its holding from 34.33% to 34.04% on a fully diluted basis.
This is a non-cash, scheme-based share issuance to promoter group entities as consideration for the merger of Ind-Swift Limited into the listed company. The promoter group's voting control is now stronger at 39.50%, though still well below 50%, so no change-of-control concerns arise. No fresh equity was issued to public shareholders, so there is no dilution impact for existing public investors.